Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

VYD-2311 is under clinical development by Invivyd and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Researchers have discovered that healthy skin — once thought to be a passive barrier — can actually produce antibodies that fight off infections. It’s hoped that the finding could one day lead to the ...

Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), comments on the many viruses that could cause pandemics that are going around already.

Covid symptoms have largely stayed the same over the last few years: cough, congestion, fever, a sore throat, nausea, ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...

The agency authorized revised fact sheets for health care providers to include additional information on susceptibility of SARS-CoV-2 variants to each of the monoclonal antibody therapies that are ...

Request To Download Free Sample of This Strategic Report @ Catalysts of Market Growth: The buoyant growth trajectory of the global monoclonal antibodies market is propelled by a convergence of ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and safety.